ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
-93.0%+656.8 pts over 5 years
Net margin
-80.2%+676.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -46.1% | -26.4% | +53.8% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -34.2% | -28.9% | |
| Return on assets | – | -25.8% | -21.4% | |
| Current ratio | – | 9.45 | 6.64 | |
| Debt to equity | – | 0.04 | – | |
| Net debt to EBITDA | – | 6.34× | – | |
| Capex to revenue | – | 18.3% | 0.3% | |
| Diluted shares | – | 20M | 27M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arcturus Therapeutics generated $319.15M from operations and spent $14.91M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$319.15M
Used
$14.91M
Capital expenditure$14.91M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-80.2%
×Asset turnover0.27×
×Equity multiplier1.35×
=Return on equity, FY2025-28.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -80.2% | 0.27× | 1.35× | -28.9% |
| FY2024 | -53.1% | 0.39× | 1.49× | -31.2% |
| FY2023 | -17.8% | 0.38× | 1.60× | -10.8% |
| FY2022 | 4.5% | 0.49× | 1.69× | 3.8% |
| FY2021 | -1648.0% | 0.03× | 1.39× | -65.2% |
| FY2020 | -756.3% | 0.03× | 1.32× | -34.2% |
| FY2019 | -125.0% | 0.33× | 3.20× | -131.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$65.78M
- Cash generatingOperating cash flow above zero-$74.27M
- Return on assets improvedROA up on the prior year-18.8% → -19.1%
- Earnings backed by cashOperating cash flow above net income-$74.27M vs -$65.78M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.67 → 6.64
- No dilutionShare count did not rise27M → 27M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.35 → 0.24